Are Allergy Shots Better Than Pills? Disease-Modifying vs Symptomatic Evidence

Allergy pills — second-generation antihistamines (cetirizine, loratadine, fexofenadine) and intranasal corticosteroids (fluticasone, mometasone) — work by blocking or suppressing the downstream effects of the allergic response. Antihistamines block H1 histamine receptors, preventing the symptom cascade once histamine is released. Intranasal steroids reduce local nasal inflammation. Neither changes the underlying IgE sensitization or shifts the immune system away from Th2 allergy toward regulatory tolerance. Allergy shots (SCIT) retrain the immune system to stop overreacting to allergens in the first place — raising IgG4 blocking antibodies, expanding regulatory T cells, reducing allergen-specific IgE. This is the mechanism distinction that makes SCIT disease-modifying per Cox 2011 PP3. Stop the pill, and symptoms return within hours. Complete a SCIT course, and remission often persists for years.

For patients with moderate-to-severe symptoms — seasonal rhinitis requiring daily medication, allergic asthma, or symptoms that significantly affect quality of life — the 3-5 year investment in SCIT is generally considered worthwhile against a decades-long future of daily pills. Cost-effectiveness analysis (Cox L, Murphey A, Hankin C, Immunol Allergy Clin North Am 2020;40[1]:69-85, PMID 31761122) shows SCIT becomes cost-effective vs standard drug therapy from approximately 6 years after initiation. The Cochrane evidence base (Calderón 2007, n=51 RCTs) supports a clinically meaningful symptom reduction (SMD −0.73) with the unique property that benefit persists years after stopping (Durham 1999 NEJM). For mild, well-controlled seasonal symptoms, the pills-vs-shots calculus may favor pills. The choice should be individualized with the allergist.

Yes — many patients continue antihistamines or intranasal steroids during the allergy shot build-up phase, particularly to manage breakthrough symptoms during pollen season. Allergy shots and antihistamine pills are not mutually exclusive; they address different parts of the allergic response. However, taking antihistamines immediately before an allergy shot can suppress the local arm reaction that clinicians use to assess dose tolerance — some allergists prefer patients not take antihistamines on the day of the injection, or at least not within 2-4 hours before. Discuss your current medication regimen with your allergist at the outset of SCIT, including OTC antihistamines and intranasal steroids, so they can advise on timing relative to injection visits.

Yes — reduction in medication use is one of the primary outcome measures in SCIT clinical trials. Cochrane Calderón 2007 (DOI 10.1002/14651858.CD001936.pub2, n=51 RCTs / 2,871 patients) found medication-use SMD of −0.57 (95% CI −0.82 to −0.33) for seasonal allergic rhinitis — a clinically meaningful reduction in antihistamine and intranasal steroid reliance during pollen season. During build-up, many patients still require some pharmacotherapy as the immune tolerance is being established. During maintenance and particularly after completing the course, medication need typically declines substantially. Some patients become medication-free during pollen season after completing SCIT. This medication-reduction outcome is part of the disease-modifying profile: you are not just symptom-controlling better, you are requiring less intervention.

For allergic asthma, allergy shots have unique advantages over pills that pharmacotherapy cannot match. Abramson MJ et al. (Cochrane 2010;CD001186, DOI 10.1002/14651858.CD001186.pub2) analyzed 88 SCIT trials and found an NNT of 3 to prevent one patient's asthma deterioration — a disease-modification outcome. The PAT study (Möller C et al., JACI 2002; Jacobsen L et al., Allergy 2007) showed 3-year pediatric SCIT roughly halved new-onset asthma at 10-year follow-up. Inhaled corticosteroids and bronchodilators (the primary pharmacotherapy for asthma) are symptomatic and anti-inflammatory but do not modify the underlying IgE sensitization driving allergic asthma. In patients with mild-to-moderate controlled allergic asthma, SCIT is indicated (Cox 2011 PP3) — uncontrolled asthma is a contraindication to SCIT, not a reason to avoid it long-term once controlled.

For immediate, acute allergy symptom relief, antihistamines work faster than allergy shots. Oral antihistamines begin suppressing histamine-mediated symptoms within 1-2 hours of ingestion; intranasal steroids take a few days to reach full effect. Allergy shots do not provide same-day symptom relief — they require 3-6 months of build-up before meaningful improvement, and full benefit is typically reached at 12-18 months of consistent treatment (Cochrane Calderón 2007). If you need relief during today's pollen exposure, an antihistamine is the appropriate tool. If you want to reduce your need for that antihistamine over the next 5-10 years, SCIT is the mechanism to pursue. The two are complementary — most patients use antihistamines during the build-up phase while the shots take effect.